Haoxi Health & Eaglepoint AI Bet on China's Digital Health Frontier

BEIJING – March 03, 2026 – In a significant move that underscores the convergence of digital marketing and advanced technology, Beijing-based Haoxi Health Technology (NASDAQ: HAO) has announced a three-year strategic partnership with Eaglepoint AI, a subsidiary of Global Mofy AI (NASDAQ: GMM). The collaboration aims to develop and launch an ambitious AI-powered health management platform in China, marking a bold pivot for Haoxi Health from a marketing services provider into the burgeoning field of AI-enabled healthcare.

The partnership seeks to fuse Haoxi's vast user reach with Eaglepoint's technical prowess to create what they hope will be a new standard in personalized, preventive healthcare for the world's most populous nation. The first phase of their joint effort will introduce the "AI Digital Health Manager," a SaaS system targeting China's large sub-healthy and chronic disease populations with services like intelligent nutrition and risk assessment.

A Strategic Bet on China's AI Health Boom

The timing of this venture is no coincidence. It aligns directly with the explosive growth of China's AI healthcare market, a sector buoyed by government support, massive data availability, and surging consumer demand for better health outcomes. Market projections paint a picture of exponential growth, with some analysts forecasting the market to skyrocket from approximately US$1.59 billion in 2023 to over US$18.8 billion by 2030, representing a compound annual growth rate of nearly 43%.

This growth is actively encouraged by national policy. The Chinese government's "Healthy China 2030" plan and the more recent "AI+" Action Plan explicitly prioritize the integration of artificial intelligence into the healthcare ecosystem. These initiatives aim to establish high-quality healthcare datasets and promote the widespread adoption of AI-assisted diagnostics, particularly in primary care settings. The partnership between Haoxi and Eaglepoint appears custom-built to capitalize on this top-down push, entering a competitive landscape populated by innovative startups and established tech giants like Ping An.

From Ad Clicks to Health Metrics: Haoxi's Transformation

For Haoxi Health, this partnership represents a fundamental strategic evolution. The company built its reputation as an online marketing specialist for the healthcare industry, helping clients acquire customers through targeted advertising on China's dominant digital platforms like Douyin, Toutiao, and WeChat. Its business has been rooted in analyzing ad performance and optimizing marketing spend.

In the announcement, Haoxi Health's CEO, Mr. Fan Zhen, highlighted this background as a key asset. "The company has long served domestic and international healthcare clients, managing tens of billions of online advertising data points," he stated. "We understand clients' urgent demand for personalized, quantifiable health management solutions." This move signals a deliberate strategy to transition from merely facilitating patient acquisition for healthcare providers to becoming a direct-to-consumer health technology provider itself. The company is betting that its deep experience in managing massive data streams and understanding online user behavior—its "marketing traffic advantages"—can be repurposed to power a sophisticated health management platform.

The 'Data + Algorithm + Traffic' Playbook

The collaboration is structured around a popular business model in China's tech scene: "Data + Algorithm + Traffic." Haoxi provides the traffic and access to a vast pool of potential users. Eaglepoint AI supplies the core algorithmic and technical engine.

Eaglepoint AI, which positions itself as a provider of "Precision AI Training by Domain Experts," brings a team that includes licensed medical professionals and partnerships with major generative AI players like NVIDIA, AWS, and OpenAI. The company specializes in preparing high-quality, sector-specific data for training advanced AI models. According to the press release, Eaglepoint will deploy its proprietary Aquila data engine and multimodal model evaluation system for the first time in a health management context.

The company claims this platform is a significant differentiator. Mr. Fan Zhen noted that Eaglepoint's Aquila platform has achieved "automated comparative experiments with mainstream large models including Claude, GPT, and Gemini, improving model iteration efficiency by 3.5 times." While this specific efficiency metric is company-reported and not yet independently verified, it speaks to the core technical value proposition: the ability to rapidly develop, test, and refine the complex algorithms needed for personalized health recommendations. This technical capability is what Haoxi hopes will transform its marketing reach into a tangible health service.

Navigating the Gauntlet of Data Privacy and Regulation

While the market opportunity is immense and the strategic logic is clear, the venture faces formidable challenges, chief among them China's stringent regulatory environment for data privacy. The proposed "AI Digital Health Manager" will process highly sensitive health information, from dietary habits to chronic disease markers. Under China's Personal Information Protection Law (PIPL), such data requires "separate consent" and must be handled with "stringent protective measures."

Navigating this legal framework will be a critical test. The partnership must design a system that not only delivers on its promise of personalization but also guarantees compliance and builds user trust. Any misstep in data handling could lead to severe penalties and reputational damage. Furthermore, the legal framework for assigning liability when an AI system makes an error in a healthcare context remains a grey area in China, posing a potential risk for the platform's operators.

Beyond data privacy, the platform's applications, especially those related to digital therapeutics and risk assessment, may fall under the purview of the National Medical Products Administration (NMPA), which has been steadily increasing its oversight of AI-powered medical devices. Securing the necessary approvals could be a lengthy and complex process. The success of this high-stakes partnership will ultimately depend not just on the synergy of their data and algorithms, but on their ability to expertly navigate this complex and evolving gauntlet of legal and regulatory hurdles.